



UN-AUDITED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SECOND QUARTER (Q2) ENDED 31 DECEMBER 2024

In compliance with the Listing Regulations 2015 of the Exchanges, we are pleased to publish the un-audited Second quarter's (Q2) Consolidated Financial Statements of Advanced Chemical Industries PLC ended 31 December 2024 along with requisite comparative financial indicators, as adopted by the Board of Directors in its 222nd meeting held on Thursday, 30 January 2025 at 4:00 pm through Hybrid system at ACI Centre. The detail financial statements have duly been dispatched to Bangladesh Securities and Exchange Commission as well as Stock Exchanges.

Consolidated statement of financial position (Un-audited)			Consolidated statement of profit or loss (Un-audited)					Consolidated statement of profit or loss and other comprehensive income (Un-audited)						
Figures in '000' Taka			Figures in '000' Taka					Figures in '000' Taka						
	As at 31 December 2024	As at 30 June 2024	For the half year ended from July 2024 to December 2024		For the 2nd Quarter ended from July 2023 to December 2023		For the half year ended from July 2024 to December 2024		For the 2nd Quarter ended from July 2023 to December 2023		For the half year ended from July 2024 to December 2024		For the 2nd Quarter ended from July 2023 to December 2023	
Assets														
Property, plant and equipment	34,433,735	33,811,986												
Right-of-use assets	3,004,111	3,184,834												
Equity-accounted investees	2,276,099	2,920,871												
Other investments	1,192,548	1,131,177												
Intangible assets	1,419,025	1,415,465												
Biological assets	57,848	52,493												
Deferred tax assets	656,845	532,202												
Non-current assets	43,040,212	43,049,028												
Inventories	24,358,476	21,290,152												
Trade receivables	21,296,287	17,639,830												
Other receivables	1,127,576	1,021,788												
Advances, deposits and prepayments	6,948,984	4,631,596												
Current tax assets	673,037	675,485												
Short term investments	201,857	196,492												
Cash and cash equivalents	6,769,377	5,590,360												
Current assets	61,375,594	51,045,703												
Total assets	104,415,806	94,094,731												
Equity														
Share capital	878,612	762,056												
Share premium	1,309,016	1,254,116												
Merger consideration shares reserve	-	56,854												
Reserves	5,961,729	6,069,477												
Accumulated loss	(2,146,167)	(1,176,671)												
Equity attributable to owners of the Company	6,003,190	6,965,832												
Non-controlling interests	1,415,295	1,591,894												
Total equity	7,418,485	8,557,727												
Liabilities														
Employee benefits	2,263,697	1,986,827												
Long term borrowings	5,641,196	6,943,562												
Non-current portion of lease liabilities	2,440,980	2,520,229												
Non-current liabilities	10,345,873	11,450,618												
Bank overdraft	11,140,919	8,697,868												
Loans and borrowings	56,631,252	48,020,336												
Current portion of lease liabilities	600,830	569,534												
Trade payables	7,336,510	7,424,167												
Other payables	10,562,189	9,364,909												
Unclaimed/unpaid dividend account	379,748	9,572												
Current liabilities	86,651,447	74,086,386												
Total liabilities	96,997,320	85,537,004												
Total equity and liabilities	104,415,806	94,094,731												
Net asset value (NAV) per share (in Taka)	68.33	79.28												
Revenue	66,197,421	62,443,329	36,487,726	32,038,033										
Cost of sales	(49,534,668)	(47,665,312)	(27,310,449)	(24,582,226)										
Gross profit	16,662,753	14,778,017	9,177,277	7,455,807										
Administrative, selling and distribution expenses	(11,679,431)	(11,258,637)	(6,277,599)	(5,674,101)										
Other income/(loss)	207,952	112,662	124,918	(30,370)										
Operating profit	5,191,274	3,632,043	3,024,596	1,751,336										
Share of the profit of equity accounted investees	257,313	317,447	147,222	159,847										
Net finance costs	(4,436,700)	(3,096,259)	(2,310,498)	(1,561,785)										
Profit before contribution to WPPF	1,011,887	853,231	861,320	349,398										
Contribution to WPPF	(253,341)	(196,740)	(169,291)	(120,831)										
Profit before tax	758,546	656,491	692,028	228,567										
Income tax expense	(1,404,579)	(1,147,951)	(868,918)	(578,933)										
Profit/(loss) after tax	(646,033)	(491,460)	(176,889)	(350,366)										
Profit/(loss) attributable to:														
Owners of the Company	(702,093)	(641,780)	(278,530)	(483,888)										
Non-controlling interests	56,060	150,320	101,641	133,522										
Profit/(loss) after tax	(646,033)	(491,460)	(176,889)	(350,366)										
Earnings per share														
Basic and diluted earnings per share (EPS) (in Taka)	(7.99)	(7.30)	(3.17)	(5.51)										

Consolidated statement of changes in equity (Un-audited)											
Figures in '000' Taka											
For the half year ended from July 2024 to December 2024											
Attributable to owner of the Company											
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Accumulated loss	Total	Non-controlling Interests	Total equity
Balance at 1 July 2024	762,056	1,254,116	56,854	1,671	(57,081)	272,821	5,852,066	(1,176,671)	6,965,832	1,591,894	8,557,727
Total comprehensive income											
Profit/(loss) after tax	-	-	-	-	-	-	(702,093)	(702,093)	56,060	(646,033)	
Other comprehensive income, net of tax	-	-	-	-	(103,802)	(3,946)	-	(107,748)	(8,026)	(115,774)	
Total comprehensive income	-	-	-	-	(103,802)	(3,946)	(702,093)	(809,840)	48,034	(761,806)	
Transaction with owners of the Company											
Issuance of merger consideration share	1,954	54,900	(56,854)	-	-	-	-	-	-	-	-
Stock dividend	114,602	-	-	-	-	-	-	(114,602)	-	-	-
Cash dividend	-	-	-	-	-	-	-	(152,802)	(152,802)	(226,933)	(379,735)
Capital contribution by non-controlling interests	-	-	-	-	-	-	-	-	-	2,300	2,300
Total transactions with owners of the Company	116,555	54,900	(56,854)	-	-	-	-	(267,404)	(152,802)	(224,633)	(377,435)
Balance at 31 December 2024	878,612	1,309,016	-	1,671	(160,883)	268,875	5,852,066	(2,146,167)	6,003,190	1,415,295	7,418,485
For the half year from July 2023 to December 2023											
Attributable to owner of the Company											
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2023	762,056	1,254,116	-	1,671	(120,987)	389,978	5,860,112	515,470	8,662,417	1,884,856	10,547,273
Total comprehensive income											
Profit/(loss) after tax	-	-	-	-	-	-	-	(641,780)	(641,780)	150,320	(491,460)
Other comprehensive income, net of tax	-	-	-	-	(168,390)	(5,361)	-	(173,751)	(15,296)	(189,047)	
Total comprehensive income	-	-	-	-	(168,390)	(5,361)	-	(641,780)	(815,531)	135,024	(680,507)
Transaction with owners of the Company											
Stock dividend	-	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	(304,823)	(304,823)	(347,706)	(652,529)
Total transactions with owners of the Company	-	-	-	-	-	-	-	(304,823)	(304,823)	(347,706)	(652,529)
Balance at 31 December 2023	762,056	1,254,116	-	1,671	(289,378)	384,617	5,860,112	(431,132)	7,542,063	1,672,174	9,214,238

Consolidated statement of cash flows (Un-audited)		
Figures in '000' Taka		
	For the half year ended from	
	July 2024 to December 2024	July 2023 to December 2023
Cash flows from operating activities		
Cash receipts from customers and others	62,115,572	58,906,614
Cash paid to suppliers and employees	(61,908,021)	(61,739,007)
Cash generated from/(used in) operating activities	207,551	(2,832,393)
Paid to WPPF	(235,746)	(328,233)
Finance costs paid	(4,068,022)	(2,321,230)
Income tax paid	(1,489,652)	(1,288,202)
	(5,793,420)	(3,937,665)
Net cash from/(used in) operating activities*	(5,585,869)	(6,770,058)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(229,726)	(770,282)
Payments for capital work-in-progress	(1,246,911)	(1,657,315)
Sale proceeds from property, plant and equipment	9,452	223
Purchase of biological assets	(6,746)	(1,184)
Dividend received	959,543	352,000
Short term investments	(5,365)	2,591,725
Long term investments	(164,457)	(191,605)
Net cash from/(used in) investing activities	(684,211)	323,563
Cash flows from financing activities		
Dividend paid	-	(103)
Dividend paid to non-controlling interests	(13)	(6)
Payment for lease liabilities	(283,026)	(248,571)
Short-term borrowing received/(paid)	6,468,204	3,144,331
Long-term borrowing received/(paid)	(1,180,638)	1,803,758
Net cash from/(used in) financing activities	5,004,527	4,699,410
Net increase/(decrease) in cash and cash equivalents	(1,265,553)	(1,747,085)
Opening cash and cash equivalents	(3,107,509)	(3,154,964)